Skip to main content
Top

20-09-2017 | Ovarian cancer | Article

Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer

Journal: BMC Cancer

Authors: Fiona R. James, Mercedes Jiminez-Linan, Jennifer Alsop, Marie Mack, Honglin Song, James D. Brenton, Paul D. P. Pharoah, H. Raza Ali

Publisher: BioMed Central

Abstract

Background

There is evidence that some ovarian tumours evoke an immune response, which can be assessed by tumour infiltrating lymphocytes (TILs). To facilitate adoption of TILs as a clinical biomarker, a standardised method for their H&E visual evaluation has been validated in breast cancer.

Methods

We sought to investigate the prognostic significance of TILs in a study of 953 invasive epithelial ovarian cancer tumour samples, both primary and metastatic, from 707 patients from the prospective population-based SEARCH study. TILs were analysed using a standardised method based on H&E staining producing a percentage score for stromal and intratumoral compartments. We used Cox regression to estimate hazard ratios of the association between TILs and survival.

Results

The extent of stromal and intra-tumoral TILs were correlated in the primary tumours (n = 679, Spearman’s rank correlation = 0.60, P < 0.001) with a similar correlation in secondary tumours (n = 224, Spearman’s rank correlation = 0.62, P < 0.001). There was a weak correlation between stromal TIL levels in primary and secondary tumour samples (Spearman’s rank correlation = 0.29, P < 0.001) and intra-tumoral TIL levels in primary and secondary tumour samples (Spearman’s rank correlation = 0.19, P = 0.0094). The extent of stromal TILs differed between histotypes (Pearson chi2 (12d.f.) 54.1, P < 0.0001) with higher levels of stromal infiltration in the high-grade serous and endometriod cases. A significant association was observed for higher intratumoral TIL levels and a favourable prognosis (HR 0.74 95% CI 0.55–1.00 p = 0.047).

Conclusion

This study is the largest collection of epithelial ovarian tumour samples evaluated for TILs. We have shown that stromal and intratumoral TIL levels are correlated and that their levels correlate with clinical variables such as tumour histological subtype. We have also shown that increased levels of both intratumoral and stromal TILs are associated with a better prognosis; however, this is only statistically significant for intratumoral TILs. This study suggests that a clinically useful immune prognostic indicator in epithelial ovarian cancer could be developed using this technique.
Literature
1.
Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed
2.
Agarwal R, Kaye SB. Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol. 2005;16(1):4–6.CrossRefPubMed
3.
Kandalaft LE, et al. Immunotherapy for ovarian cancer: what's next? J Clin Oncol. 2011;29(7):925–33.CrossRefPubMed
4.
Woo EY, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61(12):4766–72.PubMed
5.
Zhang L, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13.CrossRefPubMed
6.
Curiel TJ, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–9.CrossRefPubMed
7.
Sato E, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–43.CrossRefPubMedPubMedCentral
8.
Hamanishi J, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–5.CrossRefPubMedPubMedCentral
9.
Tomsova M, et al. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol. 2008;108(2):415–20.CrossRefPubMed
10.
Shah CA, et al. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol. 2008;109(2):215–9.CrossRefPubMed
11.
Adams SF, et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer. 2009;115(13):2891–902.CrossRefPubMedPubMedCentral
12.
Clarke B, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22(3):393–402.CrossRefPubMed
13.
Leffers N, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009;58(3):449–59.CrossRefPubMed
14.
Stumpf M, et al. Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer. 2009;101(9):1513–21.CrossRefPubMedPubMedCentral
15.
Webb JR, et al. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol. 2016 May;141(2):293–302.CrossRefPubMed
16.
Darb-Esfahani S, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2016 Jan 12;7(2):1486–99.CrossRefPubMed
17.
Woulters MC, et al. Size matters: survival benefit conferred by intratumoral T cells is dependent on surgical outcome, treatment sequence and T cell differentiation. Oncoimmunology. 2016 Jan 4;5(5):e1122863.CrossRef
18.
Bösmüller HC, et al. Combined Immunoscore of CD103 and CD3 identifies long-term survivors in high-grade serous ovarian cancer. Int J Gynecol Cancer. 2016 May;26(4):671–9.CrossRefPubMed
19.
Strickland KC, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22;7(12):13587–98.CrossRefPubMedPubMedCentral
20.
Kroeger DR, et al. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, Cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res. 2016 Jun 15;22(12):3005–15.CrossRefPubMed
21.
Tothill RW, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198–208.CrossRefPubMed
22.
Galon J, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014;232(2):199–209.CrossRefPubMed
23.
Salgado R, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26(2):259–71.CrossRefPubMed
24.
Song H, et al. Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis. 2006;27(11):2235–42.CrossRefPubMed
25.
Azzato EM, et al. Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br J Cancer. 2009;100(11):1806–11.CrossRefPubMedPubMedCentral
26.
Joyce JA, et al. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015. Apr 3;348(6230):74–80.CrossRefPubMed